​

DexCom (DXCM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DXCM Stock Forecast

DexCom (DXCM) stock forecast, based on 46 Wall Street analysts, predicts a 12-month average price target of $81.36, with a high of $146.00 and a low of $28.13. This represents a 18.38% increase from the last price of $68.73.

- $30 $60 $90 $120 $150 High: $146 Avg: $81.36 Low: $28.13 Last Closed Price: $68.73

DXCM Stock Rating

DexCom stock's rating consensus is Buy, based on 46 Wall Street analysts. The breakdown includes 1 Strong Buy (2.17%), 35 Buy (76.09%), 9 Hold (19.57%), 1 Sell (2.17%), and 0 Strong Sell (0.00%).

Buy
Total 46 1 9 35 1 Strong Sell Sell Hold Buy Strong Buy

DXCM Price Target Upside V Benchmarks

TypeNameUpside
StockDexCom18.38%
SectorHealthcare Stocks 35.25%
IndustryMedical Device Stocks21.20%

Price Target Trends

1M3M12M
# Anlaysts--11
Avg Price Target--$112.86
Last Closing Price$68.73$68.73$68.73
Upside/Downside--64.21%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 254173--24
Mar, 253174--24
Feb, 255174--26
Jan, 255165--26
Dec, 245155--25
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 08, 2024Shagun SinghRBC Capital$120.00$68.6274.88%74.60%
Aug 22, 2024Mathew BlackmanStifel Nicolaus$100.00$72.2838.35%45.50%
Aug 16, 2024Shagun SinghRBC Capital$130.00$72.3679.66%89.15%
Jul 29, 2024Matt MiksicBarclays$113.00$64.0076.56%64.41%
Jul 26, 2024Steven LichtmanOppenheimer$115.00$107.856.63%67.32%
Jul 26, 2024Matt O\'BrienPiper Sandler$90.00$63.2242.36%30.95%
Jul 26, 2024William PlovanicCanaccord Genuity$89.00$107.85-17.48%29.49%
Jul 26, 2024Shagun SinghRBC Capital$72.50$31.77128.20%5.49%
Jul 12, 2024Mathew BlackmanStifel Nicolaus$132.00$112.6617.17%92.06%
Jun 03, 2024Steven LichtmanOppenheimer$150.00$115.2330.17%118.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 08, 2025Wells FargoOverweightOverweighthold
Jan 08, 2025BernsteinOutperformOutperformhold
Dec 11, 2024CitigroupBuyBuyhold
Oct 22, 2024Piper SandlerOverweightOverweighthold
Oct 08, 2024RBC CapitalOutperformOutperformhold
Sep 24, 2024Piper SandlerOverweightOverweighthold
Aug 26, 2024Piper SandlerOverweightOverweighthold
Aug 23, 2024Wells FargoUnderperformUnderperformhold
Aug 16, 2024RBC CapitalOutperformOutperformhold
Jul 30, 2024Raymond JamesStrong BuyStrong Buyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.31$0.56$0.88$1.40-----
Avg Forecast$0.76$0.71$0.80$1.44$1.69$2.02$2.45$3.11$3.85
High Forecast$0.78$0.73$0.81$1.48$1.74$2.19$2.77$3.26$3.89
Low Forecast$0.75$0.69$0.78$1.40$1.60$1.79$2.01$2.95$3.82
Surprise %72.37%-21.13%10.00%-2.78%-----

Revenue Forecast

$2B $3B $4B $5B $6B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.93B$2.45B$2.91B$3.62B-----
Avg Forecast$1.91B$2.45B$2.91B$3.60B$4.02B$4.61B$5.31B$6.26B$7.15B
High Forecast$1.95B$2.50B$2.93B$3.63B$4.03B$4.65B$5.31B$6.30B$7.21B
Low Forecast$1.88B$2.41B$2.87B$3.58B$4.00B$4.59B$5.30B$6.22B$7.11B
Surprise %0.73%-0.00%0.16%0.56%-----

Net Income Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$493.60M$154.70M$341.20M$541.50M-----
Avg Forecast$469.89M$108.96M$212.70M$541.50M$680.80M$779.93M$954.91M$1.32B$1.64B
High Forecast$563.87M$140.14M$265.56M$676.08M$739.43M$931.55M$1.18B$1.39B$1.65B
Low Forecast$375.91M$77.78M$159.84M$406.92M$679.93M$759.83M$856.02M$1.26B$1.63B
Surprise %5.05%41.98%60.41%------

DXCM Forecast FAQ

Is DexCom stock a buy?

DexCom stock has a consensus rating of Buy, based on 46 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 35 Buy, 9 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that DexCom is a favorable investment for most analysts.

What is DexCom's price target?

DexCom's price target, set by 46 Wall Street analysts, averages $81.36 over the next 12 months. The price target range spans from $28.13 at the low end to $146 at the high end, suggesting a potential 18.38% change from the previous closing price of $68.73.

How does DexCom stock forecast compare to its benchmarks?

DexCom's stock forecast shows a 18.38% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the medical device stocks industry (21.20%).

What is the breakdown of analyst ratings for DexCom over the past three months?

  • April 2025: 16.67% Strong Buy, 70.83% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 12.50% Strong Buy, 70.83% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 19.23% Strong Buy, 65.38% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.

What is DexCom’s EPS forecast?

DexCom's average annual EPS forecast for its fiscal year ending in December 2024 is $1.69, marking a 20.71% increase from the reported $1.4 in 2023. Estimates for the following years are $2.02 in 2025, $2.45 in 2026, $3.11 in 2027, and $3.85 in 2028.

What is DexCom’s revenue forecast?

DexCom's average annual revenue forecast for its fiscal year ending in December 2024 is $4.02B, reflecting a 11.04% increase from the reported $3.62B in 2023. The forecast for 2025 is $4.61B, followed by $5.31B for 2026, $6.26B for 2027, and $7.15B for 2028.

What is DexCom’s net income forecast?

DexCom's net income forecast for the fiscal year ending in December 2024 stands at $680.8M, representing an 25.72% increase from the reported $541.5M in 2023. Projections indicate $779.93M in 2025, $954.91M in 2026, $1.32B in 2027, and $1.64B in 2028.